Loading...
XNAS
INSM
Market cap43bUSD
Dec 05, Last price  
204.00USD
1D
-0.51%
1Q
40.59%
Jan 2017
1,441.95%
Name

Insmed Inc

Chart & Performance

D1W1MN
XNAS:INSM chart
P/E
—
P/S
119.62
EPS
—
Div Yield, %
—
Shrs. gr., 5y
14.17%
Rev. gr., 5y
21.66%
Revenues
364m
+19.17%
131,000991,0007,529,00011,699,00010,373,0006,921,0004,417,000011,500,00011,500,0000009,835,000136,467,000164,413,000188,461,000245,358,000305,208,000363,707,000
Net income
-914m
L+21.91%
-40,929,000-56,139,000-19,962,000-15,667,000118,350,000-6,434,000-59,664,000-41,374,000-56,073,000-79,159,000-118,183,000-176,273,000-192,649,000-324,277,000-254,337,000-294,090,000-434,654,000-481,534,000-749,567,000-913,772,000
CFO
-684m
L+27.53%
-27,765,000-42,204,000-25,255,000-11,992,000-11,012,000-7,722,000-30,205,000-31,012,000-46,664,000-64,416,000-100,700,000-146,708,000-159,617,000-257,977,000-250,649,000-219,348,000-363,302,000-400,439,000-536,247,000-683,882,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the treatment of patients with bronchiectasis and other neutrophil-mediated diseases; and Treprostinil Palmitil Inhalation Powder, an inhaled formulation of a treprostinil prodrug treprostinil palmitil for the treatment of pulmonary arterial hypertension and other rare pulmonary disorders. Insmed Incorporated was founded in 1988 and is headquartered in Bridgewater, New Jersey.
URL
https://insmed.com/
IPO date
Feb 15, 1991
Employees
736
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT